• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study.肾功能对华法林治疗患者出血风险的影响：一项队列研究。
Am J Kidney Dis. 2013 Feb;61(2):354-7. doi: 10.1053/j.ajkd.2012.09.012. Epub 2012 Nov 16.
2
Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.肾功能对华法林使用者国际标准化比值超治疗范围相关出血风险的影响：一项前瞻性队列研究。
Am J Kidney Dis. 2015 May;65(5):701-9. doi: 10.1053/j.ajkd.2014.11.004. Epub 2014 Nov 25.
3
Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.肾移植状态对华法林剂量、抗凝控制和出血风险的影响。
Pharmacotherapy. 2017 Nov;37(11):1366-1373. doi: 10.1002/phar.2032. Epub 2017 Nov 2.
4
Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.年龄对华法林剂量、抗凝控制和出血风险的影响。
Pharmacotherapy. 2018 Jun;38(6):588-596. doi: 10.1002/phar.2089. Epub 2018 Feb 27.
5
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.华法林抗凝过度的门诊患者结局的前瞻性研究。
Arch Intern Med. 2000 Jun 12;160(11):1612-7. doi: 10.1001/archinte.160.11.1612.
6
Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.肾功能损害、癌症合并急性静脉血栓栓塞症患者的静脉血栓栓塞复发和出血- CATCH 研究分析。
Thromb Haemost. 2018 May;118(5):914-921. doi: 10.1055/s-0038-1641150. Epub 2018 Apr 4.
7
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.在 PCI 后合并房颤的患者中，达比加群双联抗栓治疗的肾脏功能和结局。
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1553-1561. doi: 10.1016/j.jcin.2019.05.050.
8
Rates of hemorrhage during warfarin therapy for atrial fibrillation.华法林治疗心房颤动期间的出血率。
CMAJ. 2013 Feb 5;185(2):E121-7. doi: 10.1503/cmaj.121218. Epub 2012 Nov 26.
9
Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.使用美国食品药品监督管理局不良事件报告系统数据库，按年龄分层评估达比加群和华法林相关出血事件。
Int J Med Sci. 2015 Mar 28;12(4):312-21. doi: 10.7150/ijms.10703. eCollection 2015.
10
Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation.房颤患者华法林药物相互作用相关的出血风险和治疗费用。
Clin Ther. 2012 Jul;34(7):1569-82. doi: 10.1016/j.clinthera.2012.05.008. Epub 2012 Jun 19.

引用本文的文献

1
Acute kidney injury interacts with VKORC1 genotype on initiative warfarin dose among heart surgery recipients: a real-world research.急性肾损伤与 VKORC1 基因型在心脏手术患者华法林初始剂量中的相互作用：一项真实世界研究。
Sci Rep. 2023 Dec 8;13(1):21750. doi: 10.1038/s41598-023-46895-2.
2
Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function.直接口服抗凝剂试验中在整个肾功能谱中的血栓栓塞和出血结局。
Clin Pharmacol Ther. 2021 Jun;109(6):1593-1605. doi: 10.1002/cpt.2131. Epub 2021 Jan 19.
3
Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy.在接受达比加群治疗的非透析治疗的慢性肾脏病全谱患者中发生大出血的危险因素。
Am J Kidney Dis. 2021 Jul;78(1):151-153. doi: 10.1053/j.ajkd.2020.09.018. Epub 2020 Dec 2.
4
Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.年龄对华法林剂量、抗凝控制和出血风险的影响。
Pharmacotherapy. 2018 Jun;38(6):588-596. doi: 10.1002/phar.2089. Epub 2018 Feb 27.
5
Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.新诊断的肾功能不全房颤患者启动华法林治疗后的治疗范围内时间及结局
J Am Heart Assoc. 2017 Mar 1;6(3):e004925. doi: 10.1161/JAHA.116.004925.
6
Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation?与健康受试者相比，土耳其贝赫切特病患者的CYP2C9活性较低：是炎症导致的下调吗？
Eur J Clin Pharmacol. 2015 Oct;71(10):1223-8. doi: 10.1007/s00228-015-1899-7. Epub 2015 Aug 2.
7
Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.肾功能对华法林使用者国际标准化比值超治疗范围相关出血风险的影响：一项前瞻性队列研究。
Am J Kidney Dis. 2015 May;65(5):701-9. doi: 10.1053/j.ajkd.2014.11.004. Epub 2014 Nov 25.
8
The Kidney Disease Screening and Awareness Program (KDSAP): a novel translatable model for increasing interest in nephrology careers.肾脏疾病筛查与认知项目（KDSAP）：一种提高对肾脏病学职业兴趣的新型可转化模式。
J Am Soc Nephrol. 2014 Sep;25(9):1909-15. doi: 10.1681/ASN.2013090928. Epub 2014 May 29.

本文引用的文献

1
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.慢性肾脏病的定义、分类和预后：KDIGO 争议会议报告。
Kidney Int. 2011 Jul;80(1):17-28. doi: 10.1038/ki.2010.483. Epub 2010 Dec 8.
2
When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.药物研发过程中何时开展肾功能损害研究：美国食品药品监督管理局的观点
Clin Pharmacol Ther. 2009 Nov;86(5):475-9. doi: 10.1038/clpt.2009.190.
3
A new equation to estimate glomerular filtration rate.一种估算肾小球滤过率的新公式。
Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.
4
Kidney function influences warfarin responsiveness and hemorrhagic complications.肾功能会影响华法林的反应性及出血并发症。
J Am Soc Nephrol. 2009 Apr;20(4):912-21. doi: 10.1681/ASN.2008070802. Epub 2009 Feb 18.
5
Prevalence of chronic kidney disease in the United States.美国慢性肾脏病的患病率。
JAMA. 2007 Nov 7;298(17):2038-47. doi: 10.1001/jama.298.17.2038.
6
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.CYP2C9和VKORC1 1173C/T基因多态性对华法林治疗的非裔美国人和欧美裔患者出血并发症风险的影响
Clin Pharmacol Ther. 2008 Feb;83(2):312-21. doi: 10.1038/sj.clpt.6100290. Epub 2007 Jul 25.
7
Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.长期抗凝并发症的危险因素。一项多中心研究。华法林优化门诊随访研究组。
Ann Intern Med. 1993 Apr 1;118(7):511-20. doi: 10.7326/0003-4819-118-7-199304010-00005.

Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study.

作者信息

Limdi Mohit A, Crowley Michael R, Beasley T Mark, Limdi Nita A, Allon Michael

出版信息

Am J Kidney Dis. 2013 Feb;61(2):354-7. doi: 10.1053/j.ajkd.2012.09.012. Epub 2012 Nov 16.

DOI:10.1053/j.ajkd.2012.09.012
PMID:23159233
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3654383/
Abstract
摘要